Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
DEPO DepoMed Inc. daily Stock Chart
DepoMed Inc.
Index- P/E39.85 EPS (ttm)0.48 Insider Own0.40% Shs Outstand60.48M Perf Week-1.34%
Market Cap1.16B Forward P/E10.23 EPS next Y1.87 Insider Trans-2.02% Shs Float59.83M Perf Month6.57%
Income49.60M PEG1.33 EPS next Q0.30 Inst Own98.10% Short Float16.50% Perf Quarter-32.59%
Sales426.20M P/S2.71 EPS this Y173.30% Inst Trans-11.55% Short Ratio5.19 Perf Half Y-10.31%
Book/sh5.66 P/B3.38 EPS next Y133.75% ROA4.80% Target Price29.17 Perf Year21.54%
Cash/sh2.85 P/C6.71 EPS next 5Y30.00% ROE14.00% 52W Range14.38 - 33.74 Perf YTD18.75%
Dividend- P/FCF13.10 EPS past 5Y46.60% ROI25.60% 52W High-43.30% Beta1.31
Dividend %- Quick Ratio1.60 Sales past 5Y46.60% Gross Margin88.20% 52W Low33.03% ATR1.40
Employees324 Current Ratio1.70 Sales Q/Q103.70% Oper. Margin31.40% RSI (14)51.44 Volatility6.53% 7.08%
OptionableYes Debt/Eq2.38 EPS Q/Q-281.80% Profit Margin11.60% Rel Volume0.33 Prev Close19.02
ShortableYes LT Debt/Eq2.38 EarningsNov 09 AMC Payout0.00% Avg Volume1.90M Price19.13
Recom2.00 SMA200.03% SMA50-2.53% SMA200-19.60% Volume635,979 Change0.58%
Nov-11-15Upgrade WallachBeth Hold → Buy $33
Nov-11-15Reiterated ROTH Capital Buy $21 → $24
Nov-04-15Initiated Cantor Fitzgerald Buy
Oct-21-15Reiterated RBC Capital Mkts Sector Perform $32 → $26
Jul-30-15Downgrade RBC Capital Mkts Outperform → Sector Perform $26 → $32
Jul-24-15Reiterated WallachBeth Hold $26 → $33
Jul-14-15Reiterated ROTH Capital Buy $28.50 → $33
Jun-11-15Initiated Morgan Stanley Equal-Weight $23
May-12-15Reiterated RBC Capital Mkts Outperform $29 → $26
Apr-22-15Initiated Piper Jaffray Overweight $37
Apr-06-15Reiterated ROTH Capital Buy $27 → $30
Mar-13-15Downgrade WallachBeth Buy → Hold $28 → $26
Jan-16-15Upgrade ROTH Capital Neutral → Buy $25
Jan-16-15Reiterated RBC Capital Mkts Outperform $20 → $22
Dec-10-14Initiated RBC Capital Mkts Outperform $20
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Sep-30-11Initiated Auriga Buy $10
Feb-18-10Downgrade Merriman Buy → Neutral
Nov-25-15 01:57PM  Horizon Drops DepoMed Acquisition: Helps IBB Mid-Cap Performance
01:32PM  Does Your iPad Know Magic Tricks? at MarketWatch
Nov-24-15 08:00AM  Depomed to Present at Four Investor Events in December PR Newswire +6.15%
Nov-22-15 07:00AM  3 Specialty-Drug Makers Trying to Spark Investor Interest -- Are They Buys? at Motley Fool
Nov-20-15 04:42PM  Chipotle and Nike are big market movers
03:51PM  Is Depomed Inc (DEPO) Going to Burn These Hedge Funds? at Insider Monkey
02:23PM  DEPOMED INC Files SEC form 8-K, Other Events
01:33PM  Horizon Pharma Stock Rises After Depomed Chase Ends at Investor's Business Daily
11:19AM  Depomed (DEPO) Stock Lower as Horizon Pharma Withdraws Takeover Bid at TheStreet
08:55AM  Top Analyst Upgrades and Downgrades: DepoMed, Gap, Intel, IBM, Nimble Storage, Workday and Many More at 24/7 Wall St.
03:30AM  Hostile bidder pulls out of $2 billion buyout of East Bay drug maker at
01:39AM  PRESS DIGEST - Wall Street Journal - Nov 20 Reuters
Nov-19-15 10:31PM  [$$] Horizon Pharma Withdraws Bid for Depomed at The Wall Street Journal
10:05PM  Depomed Comments on Horizon Withdrawal of Offer to Acquire Company PR Newswire
09:08PM  Horizon drops hostile bid for Depomed after judge's ruling
08:30PM  Horizon Pharma withdraws offer for Depomed after court ruling
Nov-18-15 04:00PM  East Bay biotech buys drug as shareholders mull $2 billion hostile bid at
Nov-17-15 05:00PM  Depomed Inc Corporate Call to Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal scheduled for 5:00 pm ET today
04:25PM  Depomed Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal PR Newswire
01:04PM  DEPOMED INC Financials
Nov-13-15 05:17PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -5.03%
04:45PM  $2 billion offer extended by hostile bidder of East Bay drug maker at
08:00AM  Depomed Named to Deloitte's 2015 Technology Fast 500 List of Fastest Growing Companies in North America PR Newswire
Nov-11-15 04:00PM  Depomed to Present at the Stifel Healthcare Conference PR Newswire -6.18%
02:50PM  Here's Why DepoMed (DEPO) Stock Is Falling Today at TheStreet
01:45PM  Why Horizon and Express Scripts Woes Might Make DepoMed Dirt Cheap at 24/7 Wall St.
01:04PM  Specialty Pharmacy Ties Claim Next Victim; Horizon Falls 17%; DepoMed Selloff "Unwarranted," Says Janney at
Nov-10-15 04:15PM  DepoMed Reports Strong Financials for Fiscal Third Quarter of 2015 +5.47%
01:34PM  3 Midsize Drug Stocks Moving On Q3 Reports at Investor's Business Daily
Nov-09-15 08:54PM  [$$] DepoMed Lifts 2015 Guidance at The Wall Street Journal
06:08PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report
05:11PM  Depomed reports 3Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance PR Newswire
07:07AM  Q3 2015 Depomed Inc Earnings Release - After Market Close
Nov-05-15 05:21PM  Valeant Said to Make Late Payments on $17 Million to PDL at Bloomberg
Nov-03-15 05:15PM  ISS and Glass Lewis Recommend Horizon Pharma Shareholders Vote AGAINST the Issuance of Horizon Shares in Connection with Horizon's Attempted Takeover of Depomed PR Newswire
04:00PM  Depomed to Report Third Quarter Fiscal Year 2015 Financial Results on Monday, November 9, 2015 PR Newswire
Oct-24-15 11:35AM  8 Fresh Analyst Picks Called to Rise 50% to 100% at 24/7 Wall St.
Oct-23-15 11:47AM  Horizon Pharma Counters Depomed Hit On Drug Pricing at Investor's Business Daily +9.93%
Oct-22-15 05:10PM  Beyond Hillary and Bernie, drug pricing at front of another campaign at
01:38PM  Noted Biotech Analyst Doesn't Think Valeant And Horizon Are Frauds, But Did Push A Line
10:59AM  Depomed Validates Horizon Pharma Rejection Offer
08:30AM  Depomed Comments on Recent Reports Regarding Horizon Pharma's Business Model PR Newswire
Oct-20-15 07:03PM  Pricing Concerns Continue To Hit Pharma Companies at The Wall Street Journal -17.14%
02:05PM  Whats The Deal With These Sinking Stocks? at Insider Monkey
Oct-19-15 09:07AM  Why GlaxoSmithKline Management Is Hopeful about Consumer Healthcare
Oct-17-15 01:41PM  3 Biotechs Stocks That We Think The Market Has All Wrong at Motley Fool
Oct-15-15 11:47AM  Depomed Issues Statement PR Newswire +5.10%
Oct-09-15 08:09AM  Horizon passes regulatory hurdle in pursuit of Depomed
Oct-06-15 11:55AM  DEPO: NUCYNTA Has the Blockbuster Potential -7.84%
Oct-01-15 10:10AM  Facing hostile takeover, East Bay drug company execs buy more stock at
10:08AM  How Did IBBs Top 5 Pharmaceutical Small Caps Perform?
Sep-30-15 04:08PM  Squashed Takeovers And Positive Test Results Propelling These Stocks Higher at Insider Monkey +21.61%
Sep-28-15 04:47PM  10 Stocks Moving In Monday's After-Hours Session -22.14%
03:41PM  War of words heats up in $2 billion East Bay drug company takeover bid at
06:30AM  Depomed Issues Statement on ISS Report PR Newswire
Sep-23-15 10:12AM  Stock to Watch: J.C. Penney, Heron Therapeutics, Intra-Cellular Therapies at The Wall Street Journal
09:24AM  Depomed Says It Receives Favorable Patent Decision at The Wall Street Journal
08:00AM  Depomed Announces Two Favorable Decisions in Inter Partes Review Proceedings Versus Endo Pharmaceuticals PR Newswire
Sep-22-15 01:25PM  Why DepoMed is Falling 10% Today at Motley Fool -12.68%
Sep-17-15 08:02AM  DEPOMED INC Files SEC form 8-K, Other Events
Sep-16-15 06:04AM  DEPOMED INC Files SEC form 8-K, Other Events
Sep-15-15 05:18PM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer PR Newswire
Sep-14-15 04:26PM  Depomed rejects Horizon's latest takeover offer
11:36AM  DepoMed Urges Holders to Reject Horizon Offer at The Wall Street Journal
08:00AM  Depomed's Board of Directors Rejects Horizon Pharma plc's Unsolicited Exchange Offer PR Newswire
Sep-10-15 08:00AM  Depomed to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Sep-09-15 10:00AM  Depomed and The American Migraine Foundation Join Forces to Highlight Need for the Proper Diagnosis, Management and Treatment of Migraine PR Newswire
Sep-08-15 04:10PM  Pay no attention to that $2 billion offer, East Bay company tells shareholders at
10:11AM  Horizon takes hostile Depomed bid directly to shareholders
09:17AM  Depomed Issues Statement on Horizon Pharma plc's Unsolicited Exchange Offer PR Newswire
08:19AM  Horizon Pharma Begins Hostile Bid for Depomed After Rebuffs at Bloomberg
08:04AM  Horizon pushes hostile Depomed bid with shareholder offer
Sep-04-15 06:15PM  Mystery, intrigue as biotech M&A explodes at
Sep-02-15 08:00AM  Depomed's Expanded Portfolio Of Pain Management Products Led By The NUCYNTA® Franchise To Be Highlighted At PAINWeek® 2015 PR Newswire
Sep-01-15 01:46PM  Smart Money Vs. Retail Investors: Level the Playing Field
Aug-31-15 07:21AM  Depomed Sets Record Date in Response to Horizon Bid at The Wall Street Journal -5.11%
06:16AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-28-15 05:45PM  Wannabe buyer appeals to shareholders in contentious East Bay takeover at
03:28PM  This Analyst Loves Depomed And Its Nucynta Prescription
Aug-26-15 01:16PM  Depomed, Inc. Earnings Q2, 2015
Aug-21-15 01:59PM  'Haphazard approach' turns $2 billion East Bay takeover bid into snippy affair at
07:03AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-20-15 10:00AM  Horizon Pharma's failed Depomed buyout -5.60%
Aug-19-15 06:32PM  Depomed rejects Horizon Pharma's offer for the third time
05:35PM  Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc PR Newswire
Aug-17-15 07:05PM  Horizon Pharma Appears to Be on an Acquisition Spree
Aug-13-15 08:17PM  Horizon Pharma PLC -- Moody's: Horizon's new Depomed offer reduces upward credit pressure at Moody's
03:14PM  Horizon Pharma Talks to Depomed Holders About Adding Cash at Bloomberg
02:00PM  Depomed Comments on Horizon Pharma plc Letter PR Newswire
Aug-10-15 03:58PM  Investor Alert: Investigation of Depomed Announced by Holzer & Holzer, LLC Business Wire
06:08AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-07-15 07:59PM  SHAREHOLDER ALERT: The Wagner Firm Announces Investigation of the Board of Directors of DepoMed, Inc. Business Wire +9.26%
05:25PM  Depomed goes hostile against Horizon Pharmas takeover bid at Fortune
01:50PM  Will Horizon Boost its Bid for DepoMed? at
12:46PM  Depomed Says Horizon Offered To Raise Bid Sort Of at Investor's Business Daily
11:10AM  DepoMed Fires Back at Horizon Pharma
07:31AM  Depomed Says Horizon Offered to Increase Its Takeover Bid at Bloomberg
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schoeneck James APresident and CEOSep 29Option Exercise6.4263,561408,15863,561Sep 29 07:24 PM
Vargas Thadd MSenior VP, BDJun 12Sale20.705,000103,500138,153Jun 15 05:16 PM
STAPLE PETER DDirectorMay 12Option Exercise6.1810,00061,80060,000May 12 09:23 PM
Schoeneck James APresident and CEOMay 12Option Exercise6.6645,679304,13461,411May 12 09:21 PM
Vargas Thadd MSenior VP, BDApr 08Option Exercise6.1854,710338,010143,153Apr 09 04:50 PM
Vargas Thadd MSenior VP, BDJan 20Option Exercise5.0319,00095,57088,443Jan 22 06:28 PM
Schoeneck James APresident and CEODec 19Option Exercise8.3640,700340,25256,432Dec 22 09:14 AM
Gosling Matthew MSenior VP, General CounselDec 02Sale15.858,819139,80832,501Dec 03 05:36 PM
Schoeneck James APresident and CEODec 02Sale15.8536,727582,23352,930Dec 03 05:35 PM
Vargas Thadd MSenior VP, BDDec 02Sale15.858,247130,74069,443Dec 03 05:35 PM
Moretti August JChief Financial OfficerDec 02Sale15.855,33984,63922,564Dec 03 05:35 PM